missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human MLK4 (aa 897-1033) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (33%), Rat (33%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-52460 (PA5-52460. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
MLK4 or mixed lineage kinase 4 belongs to the superfamily of MAP kinase kinases (MAP3K1) which contain both ser/thr and tyr kinases activity in their catalytic domains. The structure of this kinase family incorporates an N-terminal Src homology (SH3) domain, followed by the kinase domain, a leucine zipper region, and a CDC42 /RAC -interactive binding (CRIB) motif, but divergent C-terminal regions. MLK4 is highly expressed in kidney and pancreas. MLK4 is a negative regulator of TLR4 and does not activate JNK1/MAPK8 pathway, p38/MAPK14, nor ERK2/MAPK1 pathways.
Specifications
Specifications
| Accession Number | Q5TCX8 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 84451 |
| Name | Human MLK4 (aa 897-1033) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | BC021891; cDNA sequence BC021891; dJ862P8.3; Kiaa1804; MAP3K21; Mitogen-activated protein kinase kinase kinase 21; Mitogen-activated protein kinase kinase kinase MLK4; mixed lineage kinase 4; mKIAA1804; MLK4; RGD1306091; similar to Mixed lineage kinase 4 |
| Common Name | MLK4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction